Antibodies to cardiolipin in serum

Reference concentration values ​​of anti-cardiolipin AT in serum: IgG - less than 19 IU / ml;IgA - less than 15 IU / ml;IgM is less than 10 IU / ml.

Anticardiolipin AT - AT to phospholipids( cardiolipin - di - phosphatidylglycerol) of cell membranes, the leading indicator of the presence of APS in patients. AT to cardiolipin - the main fraction of AT to phospholipids. A certain level of autoantibodies to cardiolipin is present in the blood and healthy people, but when it increases, qualitatively arises

Continuation of Table.

a new condition in the hemostasis system. These ATs interact with phospholipids of platelet membranes and vascular endothelial cells, causing their destruction and contributing to thrombosis and thromboembolism.

Increased concentration of AT is a sensitive and specific laboratory test that characterizes the risk of thrombotic complications. Patients who have an elevated concentration of AT to cardioli-pin are considered at risk for thrombosis in various diseases. In pregnancy, due to thromboembolic injury of the trophoblast and placenta, fetal death, miscarriage, placental abruption, fetal hypotrophy and hypoxia are possible.

In the diagnosis of APS, AT class IgG, IgA and IgM are determined. With AFS, antibodies of IgG and IgA class are more often detected.

The content of anti-cardiolipin AT in the blood can fluctuate both spontaneously and in response to any pathological processes in the body. In the treatment of APS, the concentration of anticardiolipin ATs may or may not change.

The content of AT-class IgM react most quickly to the effective treatment of APS( their level is reduced).In low concentrations, anticardio-lipin AT class IgM can be present in rheumatoid arthritis, Sjogren's syndrome, drug-induced lupus erythematosus, Lyme disease and syphilis.

Brain circulation disorders associated with the production of AT to phospholipids have a number of clinical features: they occur at a young age, more often in women, often recur. AT to phospho-lipids revealed in 2.4-46% of young patients with ischemic impairment of cerebral circulation( anticardiolipin AT - in 60%, VA - in 75%, both of them - in 50-75%).

The relative risk of developing strokes, miscarriages or deep vein thrombosis in patients with anticardiolipin ATs in the blood is 2-4 times higher than in patients who do not have it.

Anticardiolipin AT may appear in the following conditions: thrombocytopenia, hemolytic anemia, autoimmune diseases, SLE, rheumatoid arthritis, rheumatism, nodular polyarteritis, myocardial infarction, stroke, unstable angina, infections( tuberculosis, leprosy, staphylococcal, streptococcal, measles, mononucleosis, rubella, HIV infection), arterial hypertension, obliterating endarteritis, systemic atherosclerosis, the threat of thrombotic complications, obstetric pathology with the development of APS.